We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · May 04, 2021

Adjuvant Immunotherapy for Resected Stage 3 Melanoma: An Interview Study

The Patient


Additional Info

The Patient
Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults With Resected Stage 3 Melanoma and Their Partners
Patient 2021 Mar 24;[EPub Ahead of Print], A Livingstone, D Milne, K Dempsey, DM Muscat, AM Menzies, K Howard, MR Stockler, RL Morton

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading